{"id":"ldv-sof-fdc","safety":{"commonSideEffects":[{"rate":"15-20","effect":"Headache"},{"rate":"10-15","effect":"Fatigue"},{"rate":"5-10","effect":"Nausea"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"5-10","effect":"Insomnia"}]},"_chembl":{"chemblId":"CHEMBL607859","moleculeType":"Small molecule","molecularWeight":"265.27"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ledipasvir blocks the NS5A protein required for HCV RNA replication and virion assembly, while sofosbuvir is a nucleotide analog that inhibits the NS5B RNA-dependent RNA polymerase. Together, they provide direct-acting antiviral activity against hepatitis C virus across multiple genotypes, achieving high cure rates with minimal resistance development.","oneSentence":"LDV/SOF is a fixed-dose combination of ledipasvir (NS5A inhibitor) and sofosbuvir (nucleotide NS5B polymerase inhibitor) that directly inhibits hepatitis C virus replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:51:41.020Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chronic hepatitis C virus infection (genotypes 1, 4, 5, 6)"},{"name":"Chronic hepatitis C virus infection in patients with compensated cirrhosis"}]},"trialDetails":[{"nctId":"NCT02583685","phase":"PHASE2","title":"Switching Regimen in Treating Cirrhotic HCV GT1b Subjects","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-05-15","conditions":"Chronic Hepatitis C Infection","enrollment":138},{"nctId":"NCT02613403","phase":"PHASE2","title":"Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-12-10","conditions":"Hepatitis, Hepatitis C, Digestive System Diseases","enrollment":94},{"nctId":"NCT02555943","phase":"PHASE2, PHASE3","title":"DAAs Treatment for Chronic HCV/HBV Co-infection Patients(DASCO)","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-02","conditions":"Chronic Hepatitis C Infection, HBV Coinfection, Hepatitis B Reactivation","enrollment":23},{"nctId":"NCT02825212","phase":"PHASE2, PHASE3","title":"Efficacy of All-Oral Anti-Viral Therapy for Symptomatic Hepatitis C Virus Infection-Related Cryoglobulinemia","status":"COMPLETED","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2016-02","conditions":"Hepatitis C, Cryoglobulinemia","enrollment":10},{"nctId":"NCT02858180","phase":"PHASE4","title":"Hepatitis C Virus(HCV) Heart and Lung Study","status":"COMPLETED","sponsor":"Duke University","startDate":"2016-12","conditions":"Hepatitis C, Chronic, Heart Failure, Pulmonary Disease, Chronic Obstructive","enrollment":15},{"nctId":"NCT02613871","phase":"PHASE3","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Chronic HCV and HBV Coinfection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-12-22","conditions":"Hepatitis C Virus Infection","enrollment":111},{"nctId":"NCT02021656","phase":"PHASE3","title":"Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Participants With Chronic Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-12-10","conditions":"Chronic HCV Infection","enrollment":384},{"nctId":"NCT03036839","phase":"PHASE2","title":"Ledipasvir/Sofosbuvir in Adults With Chronic Hepatitis C Virus (HCV) Infection Who Are on Dialysis for End Stage Renal Disease","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2017-06-27","conditions":"Hepatitis C Virus Infection","enrollment":95},{"nctId":"NCT02249182","phase":"PHASE2","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination +/- Ribavirin in Adolescents and Children With Chronic HCV-Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-11-05","conditions":"Hepatitis C Virus Infection","enrollment":226},{"nctId":"NCT02868242","phase":"PHASE2","title":"Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed Dose Combination in the Treatment of Hepatitis C Virus (HCV) Infection in Pediatric Participants Undergoing Cancer Chemotherapy","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-08-28","conditions":"Hepatitis C Virus Infection","enrollment":19},{"nctId":"NCT03888729","phase":"PHASE4","title":"Simplifying HCV Treatment in Rwanda for Elsewhere in the Developing World: Pangenotypic and Retreatment Study (SHARED3)","status":"UNKNOWN","sponsor":"Partners in Health","startDate":"2019-08-26","conditions":"Hepatitis C, Chronic","enrollment":100},{"nctId":"NCT02421211","phase":"PHASE2","title":"A Study to Investigate the Pharmacokinetic Interactions Between Simeprevir and Ledipasvir in a Treatment Regimen Consisting of Simeprevir, Sofosbuvir, and Ledipasvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection","status":"COMPLETED","sponsor":"Janssen Sciences Ireland UC","startDate":"2015-05-19","conditions":"Hepatitis C, Chronic","enrollment":41},{"nctId":"NCT02591277","phase":"","title":"Use-Results Surveillance Study of Harvoni® in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-11-30","conditions":"Hepatitis C","enrollment":3294},{"nctId":"NCT02350569","phase":"PHASE2","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination Administered in Patients Infected With Chronic Genotype 1 or 4 HCV for Use in the Peri-Operative Liver Transplantation Setting","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-05-22","conditions":"Hepatitis C Virus Infection","enrollment":17},{"nctId":"NCT01987453","phase":"PHASE2","title":"Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Participants With Chronic Genotype 1 HCV Who Participated in a Prior Gilead-Sponsored HCV Treatment Study","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-07","conditions":"HCV Infection","enrollment":100},{"nctId":"NCT01984294","phase":"PHASE2","title":"Ledipasvir/Sofosbuvir Fixed-Dose Combination With Ribavirin or GS-9669 in Subjects With Chronic Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-10","conditions":"Chronic HCV Infection","enrollment":101},{"nctId":"NCT02081079","phase":"PHASE2","title":"Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination in Treatment-Naive and Treatment-Experienced Subjects With Chronic Genotype 4 or 5 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-03","conditions":"Chronic Genotype 4 HCV, Chronic Genotype 5 HCV","enrollment":85},{"nctId":"NCT02251717","phase":"PHASE2","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination (FDC) for 12 or 24 Weeks in Kidney Transplant Recipients With Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-10-14","conditions":"Hepatitis C Virus Infection","enrollment":114},{"nctId":"NCT02010255","phase":"PHASE2","title":"Ledipasvir/Sofosbuvir Fixed-Dose Combination Plus Ribavirin in Participants With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-01","conditions":"Chronic HCV Infection","enrollment":334},{"nctId":"NCT01924949","phase":"PHASE2","title":"Ledipasvir/Sofosbuvir Fixed-Dose Combination in Adults With Nosocomial Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-07","conditions":"Hepatitis C","enrollment":5},{"nctId":"NCT02301936","phase":"PHASE2","title":"Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 or 24 Weeks in Genotype 1 or 4 HCV Infected Adults With Sickle Cell Disease","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-03-02","conditions":"Hepatitis C Virus Infection","enrollment":10},{"nctId":"NCT02202980","phase":"PHASE2","title":"Efficacy and Safety of Oral Regimens for the Treatment of Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-08-04","conditions":"Chronic Hepatitis C","enrollment":273},{"nctId":"NCT02487030","phase":"PHASE3","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed Dose Combination, With or Without Ribavirin, in Egyptian Adults With Chronic Genotype 4 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-09-07","conditions":"Hepatitis C Virus Infection","enrollment":255},{"nctId":"NCT02226549","phase":"PHASE2","title":"Ledipasvir/Sofosbuvir Fixed-Dose Combination and Vedroprevir With or Without Ribavirin in Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection and Cirrhosis","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-07","conditions":"Hepatitis C Virus Infection","enrollment":47},{"nctId":"NCT02600351","phase":"PHASE3","title":"Efficacy and Safety of Ledipasvir/Sofosbuvir, With or Without Ribavirin, in HCV Infected Participants Who Have Failed Prior Treatment With Sofosbuvir-based Therapies","status":"TERMINATED","sponsor":"Gilead Sciences","startDate":"2015-11-11","conditions":"Hepatitis C Virus Infection","enrollment":87},{"nctId":"NCT01938430","phase":"PHASE2","title":"Ledipasvir/Sofosbuvir Fixed-Dose Combination + Ribavirin in Subjects With Chronic HCV With Advanced Liver Disease or Post-Liver Transplant","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-09","conditions":"Chronic HCV Infection","enrollment":339},{"nctId":"NCT01826981","phase":"PHASE2","title":"Efficacy and Safety of Sofosbuvir Containing Regimens for the Treatment of Chronic HCV Infection in Participants With Chronic Genotype 1, 2, 3, or 6 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-04","conditions":"Chronic Hepatitis C","enrollment":359},{"nctId":"NCT02457611","phase":"PHASE2","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06","conditions":"Hepatitis C Infection With HIV Co-Infection","enrollment":26},{"nctId":"NCT01726517","phase":"PHASE2","title":"Safety and Efficacy of LDV/SOF Fixed-Dose Combination (FDC) ± Ribavirin in HCV Genotype 1 Subjects","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-10","conditions":"Chronic Hepatitis C Virus","enrollment":100},{"nctId":"NCT02219685","phase":"PHASE2","title":"Ledipasvir/Sofosbuvir Fixed-Dose Combination on Cerebral Metabolism and Neurocognition in Treatment-Naive and Treatment-Experienced Participants With Chronic Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-08","conditions":"Hepatitis C Virus Infection","enrollment":40},{"nctId":"NCT01965535","phase":"PHASE2","title":"Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-Dose Combination ± Ribavirin in Cirrhotic Subjects With Chronic Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-10","conditions":"HCV Infection","enrollment":155},{"nctId":"NCT02413593","phase":"PHASE2","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-04","conditions":"Hepatitis C Virus Infection","enrollment":111},{"nctId":"NCT01975675","phase":"PHASE3","title":"Efficacy and Safety of Sofosbuvir/Ledipasvir ± Ribavirin in Japanese Participants With Chronic Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-10","conditions":"Chronic HCV Infection","enrollment":341},{"nctId":"NCT01768286","phase":"PHASE3","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin in Treatment-Experienced Subjects With Genotype 1 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-01","conditions":"Chronic Hepatitis C Virus","enrollment":441},{"nctId":"NCT02472886","phase":"PHASE3","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2015-06-17","conditions":"Hepatitis C Virus Infection","enrollment":153},{"nctId":"NCT02073656","phase":"PHASE3","title":"Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-02","conditions":"Hepatitis C Virus, HIV","enrollment":335},{"nctId":"NCT01701401","phase":"PHASE3","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination (FDC) With and Without Ribavirin for the Treatment of HCV","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2012-09","conditions":"Chronic Hepatitis C Virus","enrollment":870},{"nctId":"NCT02738333","phase":"PHASE3","title":"Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Participants With Chronic Genotype 2 HCV Infection","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-04-12","conditions":"Hepatitis C Virus Infection","enrollment":239},{"nctId":"NCT01851330","phase":"PHASE3","title":"Safety and Efficacy of Ledipasvir/Sofosbuvir Fixed-Dose Combination ± Ribavirin for the Treatment of HCV (ION-3)","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-05","conditions":"Chronic Hepatitis C Virus","enrollment":647},{"nctId":"NCT02707601","phase":"PHASE3","title":"Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV Treatment","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2016-04-01","conditions":"HIV-1 Infection, HCV Infection","enrollment":150},{"nctId":"NCT03279133","phase":"PHASE4","title":"Ledipasvir/Sofosbuvir Treatment for Hepatitis C in HCT Recipients.","status":"WITHDRAWN","sponsor":"Kaiser Permanente","startDate":"2017-09-01","conditions":"Hematopoietic Stem Cell Transplantation","enrollment":""},{"nctId":"NCT01958281","phase":"PHASE2","title":"Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal Insufficiency","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2013-10-07","conditions":"HCV Infection","enrollment":38},{"nctId":"NCT02576314","phase":"PHASE3","title":"Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT3 Infected Patients","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-05","conditions":"Chronic Hepatitis C Infection","enrollment":48},{"nctId":"NCT02482077","phase":"PHASE4","title":"Sofosbuvir Containing Regimens for the Treatment of Chronic HCV GT2 Infected Patients","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-01","conditions":"Chronic Hepatitis C Infection","enrollment":112},{"nctId":"NCT02309918","phase":"PHASE2","title":"HepNet Acute HCV IV - LDV/SOF FDC in Acute Genotype 1 Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"HepNet Study House, German Liverfoundation","startDate":"2014-11","conditions":"Acute Hepatitis C","enrollment":20},{"nctId":"NCT02125500","phase":"PHASE2","title":"Pilot Study to Assess Efficacy and Safety of Sofosbuvir/Ledipasvir Fixed-dose Combination in Treatment Experienced Subjects With Hepatitis C Virus (HCV) Genotype 1 - HIV Co-infection","status":"COMPLETED","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2014-08","conditions":"Viral Hepatitis C, HIV","enrollment":68},{"nctId":"NCT02120300","phase":"PHASE2","title":"Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2014-04","conditions":"Chronic HCV Infection","enrollment":122},{"nctId":"NCT02478229","phase":"PHASE3","title":"Early Treatment With Sofosbuvir (SOF) and Ledipasvir (LDV) to Prevent HCV Recurrence After Liver Transplantation (OLT)","status":"TERMINATED","sponsor":"University Health Network, Toronto","startDate":"2015-06","conditions":"Hepatitis C Viral Infection","enrollment":1},{"nctId":"NCT02470858","phase":"PHASE2","title":"Triple DAAs Regimen in Treating Non-cirrhotic HCV GT1b Subjects","status":"COMPLETED","sponsor":"Humanity and Health Research Centre","startDate":"2015-01","conditions":"Chronic Hepatitis C Infection","enrollment":18},{"nctId":"NCT02691728","phase":"PHASE4","title":"Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease","status":"UNKNOWN","sponsor":"Peter J. Ruane, M.D., Inc.","startDate":"2016-02","conditions":"Chronic Hepatitis C","enrollment":40},{"nctId":"NCT01260350","phase":"PHASE2","title":"Open-Labeled Study of PSI-7977 and RBV With and Without PEG-IFN in Treatment-Naïve Patients With HCV GT2 or GT3","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2010-12","conditions":"Chronic Hepatitis C Infection","enrollment":292}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"LDV/SOF FDC","genericName":"LDV/SOF FDC","companyName":"HepNet Study House, German Liverfoundation","companyId":"hepnet-study-house-german-liverfoundation","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LDV/SOF is a fixed-dose combination of ledipasvir (NS5A inhibitor) and sofosbuvir (nucleotide NS5B polymerase inhibitor) that directly inhibits hepatitis C virus replication. Used for Chronic hepatitis C virus infection (genotypes 1, 4, 5, 6), Chronic hepatitis C virus infection with compensated cirrhosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}